The story of human cytomegalovirus and cancer: Increasing evidence and open questions

Neoplasia

Volumn 11, Issue 1, 2009, Pages 1-9

  Michaelis, Martin ^a   Doerr, Hans W ^a   Cinatl Jr , Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN MDM2; TRANSCRIPTION FACTOR E2F;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER STAGING; CELL ADHESION; CELL CYCLE; CELL INVASION; CELL MIGRATION; CHROMOSOMAL INSTABILITY; ENDOTHELIUM; GLIOBLASTOMA; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOGENICITY; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; VIRUS REPLICATION;

EID: 58249118272     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81178     Document Type: Article

References (96)

1. Cinatl J, Scholz M, Kotchetkov R, Vogel JU, and Doerr HW (2004). Molecular mechanisms of the modulatory effects of HCMV infection in tumor cell biology. Trends Mol Med 10, 19-23.
2. Sinclair J (2008). Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 41, 180-185.
3. Söderberg-Nauclér C (2008). HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 41, 218-223.
4. Geder KM, Lausch R, O'Neill F, and Rapp F (1976). Oncogenic transformation of human embryo lung cells by human cytomegalovirus. Science 192, 1134-1137.
5. Geder L, Kreider J, and Rapp F (1977). Human cells transformed in vitro by human cytomegalovirus: tumorigenicity in athymic nude mice. J Natl Cancer Inst 58, 1003-1009.
6. Geder L, Laychock AM, Gorodecki J, and Rapp F (1978). Alterations in biological properties of different lines of cytomegalorivus-transformed human embryo lung cells following in vitro cultivation. IARC Sci Publ 24, 591-601.
7. Nelson JA, Fleckenstein B, Jahn G, Galloway DA, and McDougall JK (1984). Structure of the transforming region of human cytomegalovirus AD169. J Virol 49, 109-115.
8. Boldogh I, Huang ES, Rady P, Arany I, Tyring S, and Albrecht T (1994). Alteration in the coding potential and expression of H-ras in human cytomegalovirus-transformed cells. Intervirology 37, 321-329.
9. Shen Y, Zhu H, and Shenk T (1997). Human cytomagalovirus IE1 and IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic transformation in cooperation with the adenovirus E1A proteins. Proc Natl Acad Sci USA 94, 3341-3345.
10. Doniger J, Muralidhar S, and Rosenthal LJ (1999). Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin Microbiol Rev 12, 367-382.
11. Cinatl J Jr, Cinatl J, Vogel JU, Rabenau H, Kornhuber B, and Doerr HW (1996). Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology 39, 259-269.
12. Cinatl J Jr, Vogel JU, Cinatl J, Weber B, Rabenau H, Novak M, Kornhuber B, and Doerr HW (1996). Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer 65, 90-96.
13. Cinatl J Jr, Cinatl J, Vogel JU, Kotchetkov R, Driever PH, Kabickova H, Kornhuber B, Schwabe D, and Doerr HW (1998). Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res 58, 367-372.
14. Cinatl J Jr, Vogel JU, Kotchetkov R, and Doerr HW (2004). Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiol Rev 28, 59-77.
15. Castillo JP and Kowalik TF (2004). HCMV infection: modulating the cell cycle and cell death. Int Rev Immunol 23, 113-139.
16. Sanchez V and Spector DH (2008). Subversion of cell cycle regulatory pathways. Curr Top Microbiol Immunol 325, 243-262.
17. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, and Kalejta RF (2008). Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320, 797-799.
18. Song YJ and Stinski MF (2005). Inhibition of cell division by the human cytomegalovirus IE86 protein: role of the p53 pathway or cyclin-dependent kinase 1/cycli B1. J Virol 79, 2597-2603.
19. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
20. Pucci B, Kasten M, and Giordano A (2000). Cell cycle and apoptosis. Neoplasia 2, 291-299.
21. Luo MH and Fortunato EA (2007). Long-term infection and shedding of human cytomegalovirus in T98G glioblastoma cells. J Virol 81, 10424-10436.
22. Cobbs CS, Soroceanu L, Denham S, Zhang W, and Kraus MH (2008). Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res 68, 724-730.
23. Maussang D, Verzijl D, van Walsum M, Leurs R, Holl J, Pleskoff O, Michel D, van Dongen GA, and Smit MJ (2006). Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci USA 103, 13068-13073.
24. Furukawa T (1984). A variant of human cytomegalovirus derived from a persistently infected culture. Virology 137, 191-194.
25. Ogura T, Tanaka J, Kamiya S, Sato H, Ogura H, and Hatano M (1986). Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol 67, 2605-2616.
26. Murphy EA, Streblow DN, Nelson JA, and Stinski MF (2000). The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J Virol 74, 7108-7118.
27. 1 phase of the cell cycle. Proc Natl Acad Sci USA 97, 2692-2696.
28. Jiang W, Cazacu S, Xiang C, Zenklusen JC, Fine HA, Berens M, Armstrong B, Brodie C, and Mikkelsen T (2008). FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia 10, 235-243.
29. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, and Wong KK (2008). Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer. Neoplasia 10, 964-972.
30. Plati J, Bucur O, and Khosravi-Far R (2008). Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem 104, 1124-1149.
31. Zhu H, Shen Y, and Shenk T (1995). Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol 69, 7960-7970.
32. Hsu CH, Chang MD, Tai KY, Yang YT, Wang PS, Chen CJ, Wang YH, Lee SC, Wu CW, and Juan LJ (2004). HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. EMBO J 23, 2269-2280.
33. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, and Epstein SE (1994). Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265, 391-394.
34. Tsai HL, Kou GH, Chen SC, Wu CW, and Lin YS (1996). Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J Biol Chem 271, 3534-3540.
35. Tanaka K, Zou JP, Takeda K, Ferrans VJ, Sandford GR, Johnson TM, Finkel T, and Epstein SE (1999). Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation 99, 1656-1659.
36. Lukac DM and Alwine JC (1999). Effects of human cytomegalovirus major immediate-early proteins in controlling the cell cycle and inhibiting apoptosis: studies with ts13 cells. J Virol 73, 2825-2831.
37. McCormick AL (2008). Control of apoptosis by human cytomegalovirus. Curr Top Microbiol Immunol 325, 281-295.
38. Michaelis M, Kotchetkov R, Vogel JU, Doerr HW, and Cinatl J Jr (2004). Cytomegalovirus infection blocks apoptosis in cancer cells. Cell Mol Life Sci 61, 1307-1316.
39. Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarski ES, and Goldmacher VS (2001). A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci USA 98, 7829-7834.
40. McCormick AL, Skaletskaya A, Barry PA, Mocarski ES, and Goldmacher VS (2003). Differential function and expression of the viral inhibitor of caspase 8-induced apoptosis (vICA) and the viral mitochondria-localized inhibitor of apoptosis (vMIA) cell death suppressors conserved in primate and rodent cytomegaloviruses. Virology 316, 221-233.
41. Goldmacher VS, Bartle LM, Skaletskaya A, Dionne CA, Kedersha NL, Vater CA, Han JW, Lutz RJ, Watanabe S, Cahir McFarland ED, et al. (1999). A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc Natl Acad Sci USA 96, 12536-12541.
42. Norris KL and Youle RJ (2008). Cytomegalovirus proteins vMIA and m38.5 link mitochondrial morphogenesis to Bcl-2 family proteins. J Virol 82, 6232-6243.
43. Terhune S, Torigoi E, Moorman N, Silva M, Qian Z, Shenk T, and Yu D (2007). Human cytomegalovirus UL38 protein blocks apoptosis. J Virol 81, 3109-3123.
44. Moorman NJ, Cristea IM, Terhune SS, Rout MP, Chait BT, and Shenk T (2008). Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex. Cell Host Microbe 3, 253-262.
45. Reeves MB, Davies AA, McSharry BP, Wilkinson GW, and Sinclair JH (2007). Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death. Science 316, 1345-1348.
46. Soroceanu L, Akhavan A, and Cobbs CS (2008). Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455, 391-395.
47. Blaheta RA, Weich E, Marian D, Bereiter-Hahn J, Jones J, Jonas D, Michaelis M, Doerr HW, and Cinatl J Jr (2006). Human cytomegalovirus infection alters PC3 prostate carcinoma cell adhesion to endothelial cells and extracellular matrix. Neoplasia 8, 807-816.
48. Cobbs CS, Soroceanu L, Denham S, Zhang W, Britt WJ, Pieper R, and Kraus MH (2007). Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. J Neurooncol 85, 271-280.
49. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, and Cobbs CS (2002). Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360, 1557-1563.
50. Allart S, Martin H, Detraves C, Terrasson J, Caput D, and Davrinche C (2002). Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of deltaN-p73alpha. J Biol Chem 277, 29063-29068.
51. Blaheta RA, Beecken WD, Engl T, Jonas D, Oppermann E, Hundemer M, Doerr HW, Scholz M, and Cinatl J Jr (2004). Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness. Neoplasia 6, 323-331.
52. Kopfstein L and Christofori G (2006). Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 63, 449-468.
53. Cruz-Monserrate Z and O'Connor KL (2008). Integrin alpha 6 beta 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation. Neoplasia 10, 408-417.
54. Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, and van Golen KL (2008). Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 10, 797-803.
55. Streblow DN, Soderberg-Naucler C, Vieira J, Smith P, Wakabayashi E, Ruchti F, Mattison K, Altschuler Y, and Nelson JA (1999). The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99, 511-520.
56. Streblow DN, Vomaske J, Smith P, Melnychuk R, Hall L, Pancheva D, Smit M, Casarosa P, Schlaepfer DD, and Nelson JA (2003). Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. J Biol Chem 278, 50456-50465.
57. Hoever G, Vogel JU, Lukashenko P, Hofmann WK, Komor M, Doerr HW, and Cinatl J Jr (2005). Impact of persistent cytomegalovirus infection on human neuroblastoma cell gene expression. Biochem Biophys Res Commun 326, 395-401.
58. Wojtukiewicz MZ, Sierko E, Klement P, and Rak J (2001). The hemostatic system and angiogenesis in malignancy. Neoplasia 3, 371-384.
59. Goon PK, Lip GY, Boos CJ, Stonelake PS, and Blann AD (2006). Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8, 79-88.
60. Murayama T, Ohara Y, Obuchi M, Khabar KS, Higashi H, Mukaida N, and Matsushima K (1997). Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1- and NF-kappaB-binding sites of the interleukin-8 gene. J Virol 71, 5692-5695.
61. Murayama T, Mukaida N, Sadanari H, Yamaguchi N, Khabar KS, Tanaka J, Matsushima K, Mori S, and Eizuru Y (2000). The immediate early gene 1 product of human cytomegalovirus is sufficient for up-regulation of interleukin-8 gene expression. Biochem Biophys Res Commun 279, 298-304.
62. Cinatl J Jr, Kotchetkov R, Scholz M, Cinatl J, Vogel JU, Hernáiz Driever P, and Doerr HW (1999). Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53. Am J Pathol 155, 285-292.
63. Lee K, Jeon K, Kim JM, Kim VN, Choi DH, Kim SU, and Kim S (2005). Downregulation of GFAP, TSP-1, and p53 in human glioblastoma cell line, U373MG, by IE1 protein from human cytomegalovirus. Glia 51, 1-12.
64. Bentz GL and Yurochko AD (2008). Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proc Natl Acad Sci USA 105, 5531-5536.
65. Dumortier J, Streblow DN, Moses AV, Jacobs JM, Kreklywich CN, Camp D, Smith RD, Orloff SL, and Nelson JA (2008). Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J Virol 82, 6524-6535.
66. Drake CG, Jaffee E, and Pardoll DM (2006). Mechanisms of immune evasion by tumors. Adv Immunol 90, 51-81.
67. Nazarenko I, Marhaba R, Reich E, Voronov E, Vitacolonna M, Hildebrand D, Elter E, Rajasagi M, Apte RN, and Zöller M (2008). Tumorigenicity of IL-1alpha-and IL-1beta-deficient fibrosarcoma cells. Neoplasia 10, 549-562.
68. Cinatl J Jr, Scholz M, and Doerr HW (2005). Role of tumor cell immune escape mechanisms in cytomegalovirus-mediated oncomodulation. Med Res Rev 25, 167-185.
69. Powers C, DeFilippis V, Malouli D, and Früh K (2008). Cytomegalovirus immune evasion. Curr Top Microbiol Immunol 325, 333-359.
70. Nelson JA (2007). Small RNAs and large DNA viruses. N Engl J Med 357, 2630-2632.
71. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, et al. (2008). Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41, 206-212.
72. Cretney E, Degli-Esposti MA, Densley EH, Farrell HE, Davis-Poynter NJ, and Smyth MJ (1999). m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J Exp Med 190, 435-444.
73. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, and Pestka S (2000). Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci USA 97, 1695-1700.
74. Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold ME, and Schall TJ (2002). Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 76, 1285-1292.
75. Jenkins C, Garcia W, Godwin MJ, Spencer JV, Stern JL, Abendroth A, and Slobedman B (2008). Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J Virol 82, 3736-3750.
76. Michelson S, Alcami J, Kim SJ, Danielpour D, Bachelerie F, Picard L, Bessia C, Paya C, and Virelizier JL (1994). Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J Virol 68, 5730-5737.
77. Kwon YJ, Kim DJ, Kim JH, Park CG, Cha CY, and Hwang ES (2004). Human cytomegalovirus (HCMV) infection in osteosarcoma cell line suppresses GM-CSF production by induction of TGF-beta. Microbiol Immunol 48, 195-199.
78. Wick W, Naumann U, and Weller M (2006). Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des 12, 341-349.
79. Alcami J, Paya CV, Virelizier JL, and Michelson S (1993). Antagonistic modulation of human cytomegalovirus replication by transforming growth factor beta and basic fibroblastic growth factor. J Gen Virol 74, 269-274.
80. Yoo YD, Chiou CJ, Choi KS, Yi Y, Michelson S, Kim S, Hayward GS, and Kim SJ (1996). The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta1 gene through an Egr-1 binding site. J Virol 70, 7062-7070.
81. Tabata T, Kawakatsu H, Maidji E, Sakai T, Sakai K, Fang-Hoover J, Aiba M, Sheppard D, and Pereira L (2008). Induction of an epithelial integrin alphavbeta6 in human cytomegalovirus-infected endothelial cells leads to activation of transforming growth factor-beta1 and increased collagen production. Am J Pathol 172, 1127-1140.
82. Fortunato EA and Spector DH (2003). Viral induction of site-specific chromosome damage. Rev Med Virol 13, 21-37.
83. Jefford CE and Irminger-Finger I (2006). Mechanisms of chromosome instability in cancers. Crit Rev Oncol Hematol 59, 1-14.
84. Privette LM, Weier JF, Nguyen HN, Yu X, and Petty EM (2008). Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia 10, 643-652.
85. Hartmann M and Brunnemann H (1972). Chromosome aberrations in cytomegalovirus-infected human diploid cell culture. Acta Virol 16, 176.
86. Deng CZ, AbuBakar S, Fons MP, Boldogh I, and Albrecht T (1992). Modulation of the frequency of human cytomegalovirus-induced chromosome aberrations by camptothecin. Virology 189, 397-401.
87. Deng CZ, AbuBakar S, Fons MP, Boldogh I, Hokanson J, Au WW, and Albrecht T (1992). Cytomegalovirus-enhanced induction of chromosome aberrations in human peripheral blood lymphocytes treated with potent genotoxic agents. Environ Mol Mutagen 19, 304-310.
88. Fortunato EA, Dell'Aquila ML, and Spector DH (2000). Specific chromosome 1 breaks induced by human cytomegalovirus. Proc Natl Acad Sci USA 97, 853-858.
89. Baumgartner M, Schneider R, Auer B, Herzog H, Schweiger M, and Hirsch-Kauffmann M (1992). Fluorescence in situ mapping of the human nuclear NAD+ ADP-ribosyltransferase gene (ADPRT) and two secondary sites to human chromosomal bands 1q42, 13q34, and 14q24. Cytogenet Cell Genet 61, 172-174.
90. Li YS, Ramsay DA, Fan YS, Armstrong RF, and Del Maestro RF (1995). Cytogenetic evidence that a tumor suppressor gene in the long arm of chromosome 1 contributes to glioma growth. Cancer Genet Cytogenet 84, 46-50.
91. Bièche I, Champème MH, and Lidereau R (1995). Loss and gain of distinct regions of chromosome 1q in primary breast cancer. Clin Cancer Res 1, 123-127.
92. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, and Britt WJ (2002). Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62, 3347-3350.
93. Samanta M, Harkins L, Klemm K, Britt WJ, and Cobbs CS (2003). High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170, 998-1002.
94. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, and Sampson JH (2008). Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10, 10-18.
95. Prins RM, Cloughesy TF, and Liau LM (2008). Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359, 539-541.
96. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, and El-Zein R (2008). Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116, 79-86.